CHIP is considered to precede MDS and reflects the presence of mutations that are also implicated in MDS pathogenesis, thus linking these genetic alterations to inflammatory and cardiovascular outcomes [103,104]. This evidence concerns the gene STUB1 and myelodysplastic syndrome.